These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 2106723)

  • 1. Tumour necrosis factor in hepatosplenic schistosomiasis.
    Zwingenberger K; Irschick E; Vergetti Siqueira JG; Correia Dacal AR; Feldmeier H
    Scand J Immunol; 1990 Feb; 31(2):205-11. PubMed ID: 2106723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Praziquantel in the treatment of hepatosplenic schistosomiasis: biochemical disease markers indicate deceleration of fibrogenesis and diminution of portal flow obstruction.
    Zwingenberger K; Richter J; Vergetti JG; Feldmeier H
    Trans R Soc Trop Med Hyg; 1990; 84(2):252-6. PubMed ID: 2117787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High levels of TNF, soluble TNF receptors, soluble ICAM-1, and IFN-gamma, but low levels of IL-5, are associated with hepatosplenic disease in human schistosomiasis mansoni.
    Mwatha JK; Kimani G; Kamau T; Mbugua GG; Ouma JH; Mumo J; Fulford AJ; Jones FM; Butterworth AE; Roberts MB; Dunne DW
    J Immunol; 1998 Feb; 160(4):1992-9. PubMed ID: 9469463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T cell phenotype alterations in hepatosplenic schistosomiasis mansoni normalize after chemotherapy.
    Zwingenberger K; Harms G; Vergetti de Siqueira JG; Correia Dacal AR; Jansen-Rosseck R; Bienzle U; Feldmeier H
    Immunobiology; 1989 Oct; 179(4-5):342-52. PubMed ID: 2515152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered generation of interleukin 1 in chronic human schistosomiasis mansoni.
    Zwingenberger K; Richter J; Taupitz S; Vergetti Siqueira JG; Correia Dacal AR
    Scand J Immunol; 1990 Jun; 31(6):729-36. PubMed ID: 2113308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction of morbidity in hepatosplenic schistosomiasis mansoni after treatment with praziquantel: a long term study.
    Domingues AL; Coutinho AD
    Rev Soc Bras Med Trop; 1990; 23(2):101-7. PubMed ID: 2129517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hepatosplenic Schistosomiasis mansoni with praziquantel. Preliminary report on tolerance and efficacy.
    Coutinho A; Domingues AL; Neves J; Almeida ST
    Arzneimittelforschung; 1983; 33(5):787-91. PubMed ID: 6683560
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune responses during human schistosomiasis. XII. Differential responsiveness in patients with hepatosplenic disease.
    Colley DG; Garcia AA; Lambertucci JR; Parra JC; Katz N; Rocha RS; Gazzinelli G
    Am J Trop Med Hyg; 1986 Jul; 35(4):793-802. PubMed ID: 3089040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver involvement in human schistosomiasis mansoni. Regression of immunological and biochemical disease markers after specific treatment.
    Zwingenberger K; Harms G; Feldmeier H; Müller O; Steiner A; Bienzle U
    Acta Trop; 1988 Sep; 45(3):263-75. PubMed ID: 2903628
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the cytokines IL-10 and IL-13 as mediators in the progression of Symmers fibrosis in patients with hepatosplenic schistosomiasis mansoni.
    Brandt CT; Rino M; Pitta MG; Muniz JS; Silveira Dde O; Castro CM
    Rev Col Bras Cir; 2010 Oct; 37(5):333-7. PubMed ID: 21180998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver involvement in human schistosomiasis mansoni. Assessment by immunological and biochemical markers.
    Zwingenberger K; Feldmeier H; Queiroz JA; Siqueira JG; Auto HF; Alencar JE; Bienzle U
    Parasitol Res; 1988; 74(5):448-55. PubMed ID: 3137558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific treatment of hepatosplenic schistosomiasis can increase T-lymphocyte reactivity.
    Muniz-Junqueira MI; Tavares-Neto J; Ataide M; Prata A; Tosta CE
    Rev Soc Bras Med Trop; 1991; 24(2):97-9. PubMed ID: 1841433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunology of hepatosplenic schistosomiasis mansoni: a human perspective.
    Dunne DW; Pearce EJ
    Microbes Infect; 1999 Jun; 1(7):553-60. PubMed ID: 10603572
    [No Abstract]   [Full Text] [Related]  

  • 14. T cell-dependent immunodepression in vivo in Schistosoma mansoni infected patients.
    Muniz-Junqueira MI; Tosta CE; Prata A
    Rev Soc Bras Med Trop; 1990; 23(1):27-31. PubMed ID: 2128545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of hepatosplenic schistosomiasis mansoni with praziquantel].
    Coutinho AD; Domingues AL; Florêncio JN; Almeida ST
    Rev Inst Med Trop Sao Paulo; 1984; 26(1):38-50. PubMed ID: 6379831
    [No Abstract]   [Full Text] [Related]  

  • 16. Is the coagulopathy of hepatosplenic schistosomiasis immune-related?
    Amer AM; el Defrawi IE; el Sherif NH; el Khayat HR
    Blood Coagul Fibrinolysis; 1994 Oct; 5(5):789-93. PubMed ID: 7865686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Praziquantel in the treatment of the hepatosplenic form of Schistosomiasis mansoni.
    da Silva LC; Sette H; Christo CH; Sáez-Alquezar A; Carneiro CR; Lacet CM; Ohtsuki N; Raia S
    Arzneimittelforschung; 1981; 31(3a):601-3. PubMed ID: 7195256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral immune responses in human hepatosplenic schistosomiasis mansoni.
    Goodgame RW; Colley DG; Draper CC; Lewis FA; McLaren ML; Pelley RP
    Am J Trop Med Hyg; 1978 Nov; 27(6):1174-80. PubMed ID: 727322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune profiles in hepatosplenic schistosomiasis mansoni after surgical treatments.
    Petroianu A; Antunes LJ
    J Int Med Res; 1998; 26(1):43-9. PubMed ID: 9513076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical immunology of hepato-splenic bilharziasis].
    Esterre P; Boisier P; Ravaolimalala VA; Roux J
    Arch Inst Pasteur Madagascar; 1994; 61(1):28-30. PubMed ID: 7778947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.